Navigation Links
Study Finds Aspirin Still Best at Preventing 2nd Stroke
Date:5/25/2011

WEDNESDAY, May 25 (HealthDay News) -- A new drug that had shown promise in animal testing is not better than aspirin in preventing a second stoke in someone who's already had one, a new study has found.

In fact, researchers stopped the study early because the drug, terutroban, showed no extra benefit.

Previous research in animals had suggested that the drug was as effective as aspirin at preventing blood clots, and scientists had wondered whether it might have other positive effects on the human cardiovascular system.

The new study, by Dr. Marie-Germaine Bousser, of the Lariboisiere Hospital in Paris and her colleagues, compared the drug to aspirin in people who'd had an ischemic stroke, the type of stroke caused by a blocked artery. Of the more than 19,000 participants, roughly half were assigned to take terutroban, and the others took aspirin.

When tracked, on average, for the next 28 months, people who took terutroban fared no better than those on aspirin, the study found.

"In a worldwide perspective, aspirin remains the gold standard antiplatelet drug for secondary stroke prevention, in view of its efficacy, tolerance and cost," the researchers wrote.

One expert agreed.

"Allowing for the 'gentler' conclusion that there is no difference between terutroban and aspirin for stroke prevention, aspirin remains a widely available and inexpensive treatment throughout the world," said Dr. Richard B. Libman, chief of the division of vascular neurology at Long Island Jewish Medical Center in New Hyde Park, N.Y. "Any new medication for stroke prevention is going to have to do better than this before it can replace 'good old' aspirin," he said.

But in a commentary, researchers from Chang Gung University College of Medicine in Taiwan and the University of California, San Diego, wrote that there's still more to learn about whether terutroban could help people who have had a second stroke while on aspirin.

"Trials that randomly assign patients with a breakthrough event while on aspirin to a newer antiplatelet drug or higher aspirin dose, rather than re-initiation of the original aspirin dose, could provide insights into this issue," they wrote. "Perhaps terutroban could be called on to perform again."

The study, published online May 25 in The Lancet, was also to be presented Wednesday in Hamburg, Germany, at the European Stroke Conference.

More information

The U.S. National Heart, Lung, and Blood Institute has more about stroke.

-- Randy Dotinga

SOURCE: Richard B. Libman, MD FRCP(C), chief, division of vascular neurology, Long Island Jewish Medical Center, New Hyde Park, NY; The Lancet, news release, May 25, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Research study reveals profile for female drunk-drivers
2. Pelvic widening continues throughout a persons lifetime, UNC study
3. US study shows that tofacitinib is an efficacious treatment for active RA
4. Study finds much different work histories for disability rejects, beneficiaries
5. Study Ties Blood Markers to Death Risk in Heart Failure
6. Temple-led study finds widening gap between distracted driving and legislation
7. Brisk walking may help men with prostate cancer, UCSF study finds
8. New study aims to improve long-term treatment for patients with bipolar disorder
9. Medicare improved Canadian doctors salaries: Queens University study
10. IUPUI study first to look at early treatment of depression to reduce heart disease risk
11. A Cultured Man Is a Healthier, Happier Man: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Finds Aspirin Still Best at Preventing 2nd Stroke
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively new statin, ... not known to have significant interactions with antiretroviral therapy (ART). Among people ... and dampen inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... that over the last decade, student well-being has seriously declined. "When disenfranchised youth ... formal education, join the Islamic State to turn the historic multi-ethnic and multi-religious ...
(Date:4/24/2017)... ... 24, 2017 , ... Life of Purpose Treatment is proud to present “An ... held at 7:30 pm on May 10th at the University Auditorium. , This benefit ... will support the UF Collegiate Recovery Community (UFCRC). The concert will kick off the ...
(Date:4/23/2017)... ... April 23, 2017 , ... Altura ... the achievement of Cisco Select certification and SMB specialization. Altura is now ... , In earning the Select Certification, Altura fulfilled the training and exam ...
(Date:4/22/2017)... San Juan Capistrano (PRWEB) , ... April 22, 2017 , ... The San Juan ... have recently released a parenting report outlining the need for summer camps to provide physical ... , The Importance of Physical Activity In Summer Camps , With an increase in specialty ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
(Date:4/19/2017)... 19, 2017  IRIDEX Corporation (Nasdaq: IRIX ... for the first quarter 2017 after the close of ... team will host a corresponding conference call beginning at ... Investors interested in listening to the conference call may ... or (703) 326-3030 for international callers, using conference ID: ...
Breaking Medicine Technology: